Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acucela, a clinical-stage biotechnology company engaged in developing new drug therapies for blinding eye diseases, has appointed Nancy Boman as its new vice president of clinical development and regulatory affairs.
Subscribe to our email newsletter
Dr Boman comes to Acucela as a veteran of several West Coast biotech companies, most recently overseeing clinical development and regulatory affairs for Cell Therapeutics in Seattle.
She Boman has also worked in regulatory affairs capacities at Cytokinetics and Genentech in San Francisco, Amgen in Thousand Oaks, California and AnorMED and QLT in British Columbia.
Ryo Kubota, founder and CEO of Acucela, said: “Dr Boman adds a strong background in regulatory strategy that will be extremely important as we pursue a treatment for the leading cause of blindness in the aging population. Her expertise will help our growth and evolution as a specialty pharmaceutical company focused on treating degenerative eye conditions.”